Compare · NRXS vs TMDX
NRXS vs TMDX
Side-by-side comparison of Neuraxis Inc. (NRXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.00B, about 41.6x NRXS ($72.0M).
- Over the past year, NRXS is up 134.0% and TMDX is down 20.3% - NRXS leads by 154.3 points.
- NRXS has been more active in the news (13 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- TransMedics Group Inc.
- Price
- $5.71-2.73%
- $86.39-2.14%
- Market cap
- $72.0M
- $3.00B
- 1M return
- -17.19%
- -2.35%
- 1Y return
- +134.02%
- -20.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 13
- 2
- Recent ratings
- 0
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NRXS
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- CMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability
- CRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)
- Chief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation
- Neuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Director Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian
- Director Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert
- Director Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)
Latest TMDX
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)